皮膚がん診断薬の世界市場レポート 2025年

皮膚がん診断薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で46億9,000万米ドルに成長します。予測期間の成長は、日光浴に対する意識の高まり、個別化医療へのアプローチ、遠隔医療と遠隔モニタリング、ヘルスケアインフラの世界の拡大などに起因しています。予測期間の主な動向には、デジタルヘルスプラットフォームの統合、革新的な皮膚がん治療薬、学際的アプローチ、皮膚病理学の革新、患者教育と意識向上などが含まれます。

皮膚がん診断薬市場は、メラノーマの罹患率の増加によって成長する見込みです。メラニン産生細胞から発生する皮膚がんの一種であるメラノーマは、早期発見と正確な治療計画のために効果的な診断が必要です。2023年、米国がん協会は、米国における男性のメラノーマ症例数が2022年の57,180例から2023年には58,120例に増加すると報告しています。米国臨床腫瘍学会によると、メラノーマは米国で診断された皮膚がんの約1％を占めるが、皮膚がん関連死亡の主要原因であり、2023年には7,990人の命が奪われると予測されています。その結果、メラノーマの発生率の上昇が皮膚がん診断薬市場の成長を促進しています。

皮膚がん診断薬市場は、がん研究への投資拡大から恩恵を受けると予測されます。これは、がんの研究、予防、診断、治療を目的とした科学的な取り組みに財源を割り当てることを意味します。このような資金は、皮膚がん診断薬の高度な画像技術、分子診断、バイオマーカー同定などの革新的技術の開発を支援しています。例えば、2022年3月、オーストラリアの保健・高齢者医療省は、がんサービスと転帰を強化するために8億9,350万米ドルを割り当てた。このようながん研究への多額の投資は、皮膚がん診断薬の進歩に拍車をかけると期待されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界皮膚がん診断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の皮膚がん診断薬市場：成長率分析
• 世界の皮膚がん診断薬市場の実績：規模と成長, 2019-2024
• 世界の皮膚がん診断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界皮膚がん診断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の皮膚がん診断薬市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 基底細胞がん
• 扁平上皮がん
• 悪性黒色腫
• その他のがんの種類
• 世界の皮膚がん診断薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断
• 治療薬
• 世界の皮膚がん診断薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 研究室
• その他の用途
• 世界の皮膚がん診断薬市場基底細胞がんの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断画像技術
• 生検手順
• 分子診断検査
• 世界の皮膚がん診断薬市場扁平上皮がんの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断画像技術
• 生検手順
• 分子診断検査
• 世界の皮膚がん診断薬市場悪性黒色腫の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断画像技術
• 生検手順
• 分子診断検査
• 世界の皮膚がん診断薬市場、その他のがんの種類のサブセグメンテーション、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非黒色腫皮膚がん
• 隆起性皮膚線維肉腫
• メルケル細胞がん

第7章 地域別・国別分析

• 世界の皮膚がん診断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の皮膚がん診断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 皮膚がん診断薬市場：競合情勢
• 皮膚がん診断薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Sanofi
• Eli Lilly and Company
• Canon Medical Systems Corporation
• Amgen Inc.
• GE Healthcare
• Daiichi Sankyo Company Limited.
• National Cancer Institute
• Agilent Technologies Inc.
• bioMerieux SA
• Teva Pharmaceutical Industries
• Bruker Corp
• Almirall
• Genentech
• Castle Biosciences

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 皮膚がん診断薬市場2029：新たな機会を提供する国
• 皮膚がん診断薬市場2029：新たな機会を提供するセグメント
• 皮膚がん診断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Skin cancer diagnostics involve the processes and methods employed by healthcare professionals to identify and confirm the presence of skin cancer in individuals. These diagnostics typically encompass a combination of clinical examination, imaging techniques, and laboratory tests, aimed at evaluating suspicious skin lesions and assessing the extent and characteristics of the cancer.

The main types of skin cancer diagnostics include basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and others. Basal Cell Carcinoma is the most prevalent form of skin cancer, originating from the basal cells of the skin's lower epidermis. Various diagnostic and therapeutic methods are widely applied in hospitals, clinics, laboratories, and other healthcare settings.

The skin cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides skin cancer diagnostics market statistics, including skin cancer diagnostics industry global market size, regional shares, competitors with skin cancer diagnostics market share, detailed skin cancer diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the skin cancer diagnostics industry. This skin cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The skin cancer diagnostics market size has grown strongly in recent years. It will grow from $3.13 billion in 2024 to $3.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased incidence of skin cancer, growing aging population, awareness and education programs, government initiatives for early detection

The skin cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising sun exposure awareness, personalized medicine approaches, telemedicine and remote monitoring, global expansion of healthcare infrastructure. Major trends in the forecast period include integration of digital health platforms, innovative skin cancer drugs, multi-disciplinary approaches, dermatopathology innovations, patient education and awareness.

The skin cancer diagnostics market is poised for growth, driven by the increasing incidence of melanoma. Melanoma, a form of skin cancer arising from melanin-producing cells, necessitates effective diagnostics for early detection and accurate treatment planning. In 2023, the American Cancer Society reported a rise in male melanoma cases in the United States from 57,180 in 2022 to 58,120 in 2023. According to the American Society of Clinical Oncology, melanoma constitutes approximately 1% of diagnosed skin cancers in the United States but is a leading cause of skin cancer-related mortality, projected to claim 7,990 lives in 2023. Consequently, the escalating incidence of melanoma is propelling the skin cancer diagnostics market's growth.

The skin cancer diagnostics market is anticipated to benefit from increased investments in cancer research. This involves allocating financial resources to scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. Such funding supports the development of innovative technologies, including advanced imaging techniques, molecular diagnostics, and biomarker identification for skin cancer diagnostics. For instance, in March 2022, the Department of Health and Aged Care in Australia allocated $893.5 million to enhance cancer services and outcomes. This substantial investment in cancer research is expected to fuel advancements in skin cancer diagnostics.

Leading companies in the skin cancer diagnostics market are concentrating on developing innovative products, such as the PRAME protein, to improve detection and treatment strategies for melanoma and other skin cancers. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer/testis antigen that has demonstrated promise as a biomarker for melanoma diagnostics. For example, in October 2022, Roche, a Switzerland-based global healthcare company, introduced the PRAME (EPR20330) Antibody. This antibody is specifically designed to detect PRAME protein expression in tissue samples from patients suspected of having melanoma. It aids in differentiating between benign and malignant lesions, as the presence of PRAME expression indicates malignancy, which is crucial for accurate diagnosis and treatment planning.

Major players in the skin cancer diagnostics market are directing their efforts toward advanced services, including AI-powered pop-up clinics, to gain a competitive advantage. AI-powered pop-up clinics utilize artificial intelligence technologies to offer efficient and technologically advanced medical services. In January 2023, Skin Check Champions, in collaboration with The University of South Australia and The Hospital Research Foundation, introduced an AI-powered pop-up clinic dedicated to skin cancer diagnosis. Managed by nurses, this clinic captures high-quality lesion images, subjecting them to AI algorithms for preliminary diagnoses, later confirmed by local general practitioners.

In August 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Turning Point Therapeutics Inc. for an undisclosed amount. This strategic acquisition enhances Bristol's portfolio with investigational medicines targeting common oncogenic mutations, including repotrectinib. Turning Point Therapeutics, Inc., is a US-based pharmaceutical company specializing in targeted therapies for breast, ovarian, and melanoma cancer treatment.

Major companies operating in the skin cancer diagnostics market include Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Daiichi Sankyo Company Limited., National Cancer Institute, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Almirall, Genentech, Castle Biosciences, Sun Pharmaceutical Industries Limited., American Academy of Dermatology, Biolitec Ag, Alma Lasers, DermTech Inc., SkylineDx BV, DermLite LLC, AMLo Biosciences Limited

North America was the largest region in the skin cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skin cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the skin cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The skin cancer diagnostics market consists of revenues earned by entities by providing skin cancer diagnostics services such as diagnostic tests, visual inspection, dermoscopy, biopsy, imaging techniques (ultrasound, CT scan, MRI), laboratory tests (immunohistochemistry, molecular testing, genetic analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. The skin cancer diagnostics market also includes sales of dermatoscope, biopsy tools, imaging equipment (ultrasound, CT scanners, MRI machines), molecular testing kits, immunohistochemistry (IHC) kits, laboratory analysis software. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Skin Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on skin cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for skin cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The skin cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma, Other Cancer Types
• 2) By Type: Diagnosis, Therapeutics
• 3) By Application: Hospital, Clinic, Laboratory, Other Applications
• Subsegments:
• 1) By Basal Cell Carcinoma: Diagnostic imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 2) By Squamous Cell Carcinoma: Diagnostic imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 3) By Malignant Melanoma: Diagnostic Imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 4) By Other Cancer Types: Non-Melanoma Skin Cancers; Dermatofibrosarcoma Protuberans; Merkel Cell Carcinoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Limited; Merck & Co.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Skin Cancer Diagnostics Market Characteristics

3. Skin Cancer Diagnostics Market Trends And Strategies

4. Skin Cancer Diagnostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Skin Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Skin Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Skin Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Skin Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Skin Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Skin Cancer Diagnostics Total Addressable Market (TAM)

6. Skin Cancer Diagnostics Market Segmentation

• 6.1. Global Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Basal Cell Carcinoma
• Squamous Cell Carcinoma
• Malignant Melanoma
• Other Cancer Types
• 6.2. Global Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Therapeutics
• 6.3. Global Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Laboratory
• Other Applications
• 6.4. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Basal Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.5. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.6. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Malignant Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.7. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Melanoma Skin Cancers
• Dermatofibrosarcoma Protuberans
• Merkel Cell Carcinoma

7. Skin Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Skin Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Skin Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Skin Cancer Diagnostics Market

• 8.1. Asia-Pacific Skin Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Skin Cancer Diagnostics Market

• 9.1. China Skin Cancer Diagnostics Market Overview
• 9.2. China Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Skin Cancer Diagnostics Market

• 10.1. India Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Skin Cancer Diagnostics Market

• 11.1. Japan Skin Cancer Diagnostics Market Overview
• 11.2. Japan Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Skin Cancer Diagnostics Market

• 12.1. Australia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Skin Cancer Diagnostics Market

• 13.1. Indonesia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Skin Cancer Diagnostics Market

• 14.1. South Korea Skin Cancer Diagnostics Market Overview
• 14.2. South Korea Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Skin Cancer Diagnostics Market

• 15.1. Western Europe Skin Cancer Diagnostics Market Overview
• 15.2. Western Europe Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Skin Cancer Diagnostics Market

• 16.1. UK Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Skin Cancer Diagnostics Market

• 17.1. Germany Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Skin Cancer Diagnostics Market

• 18.1. France Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Skin Cancer Diagnostics Market

• 19.1. Italy Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Skin Cancer Diagnostics Market

• 20.1. Spain Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Skin Cancer Diagnostics Market

• 21.1. Eastern Europe Skin Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Skin Cancer Diagnostics Market

• 22.1. Russia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Skin Cancer Diagnostics Market

• 23.1. North America Skin Cancer Diagnostics Market Overview
• 23.2. North America Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Skin Cancer Diagnostics Market

• 24.1. USA Skin Cancer Diagnostics Market Overview
• 24.2. USA Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Skin Cancer Diagnostics Market

• 25.1. Canada Skin Cancer Diagnostics Market Overview
• 25.2. Canada Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Skin Cancer Diagnostics Market

• 26.1. South America Skin Cancer Diagnostics Market Overview
• 26.2. South America Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Skin Cancer Diagnostics Market

• 27.1. Brazil Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Skin Cancer Diagnostics Market

• 28.1. Middle East Skin Cancer Diagnostics Market Overview
• 28.2. Middle East Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Skin Cancer Diagnostics Market

• 29.1. Africa Skin Cancer Diagnostics Market Overview
• 29.2. Africa Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Skin Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Skin Cancer Diagnostics Market Competitive Landscape
• 30.2. Skin Cancer Diagnostics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Skin Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Sanofi
• 31.3. Eli Lilly and Company
• 31.4. Canon Medical Systems Corporation
• 31.5. Amgen Inc.
• 31.6. GE Healthcare
• 31.7. Daiichi Sankyo Company Limited.
• 31.8. National Cancer Institute
• 31.9. Agilent Technologies Inc.
• 31.10. bioMerieux SA
• 31.11. Teva Pharmaceutical Industries
• 31.12. Bruker Corp
• 31.13. Almirall
• 31.14. Genentech
• 31.15. Castle Biosciences

32. Global Skin Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Skin Cancer Diagnostics Market

34. Recent Developments In The Skin Cancer Diagnostics Market

35. Skin Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Skin Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Skin Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Skin Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer